A study of human tumor cells implanted in mice from the MacPherson Lab at Fred Hutch describes a new way to screen for the ...

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have progressed on prior im ...

Targeting clonal antigens and circumventing dysfunctional states may be important for conferring clinical responses to TIL therapy.

UbiVac’s DPV-001 induces Development of 1st in-patient generated TCR to Non-Small Cell Lung Cancer’s “Dark Matter” – Targets cancer without apparent toxicity UbiVac is thrilled to announce the first ...

Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer, with two patients remaining on treatment ...

An investigational viral immunotherapy extended survival compared with standard care for patients with advanced non-small cell lung cancer who had inadequate response to immune checkpoint inhibitor ...

Results from phase 2 trials appear to support the use of chemotherapy-free regimens in patients with osimertinib-resistant NSCLC.

The stock's high price tag could be a problem for investors looking for a big return. Summit Therapeutics (NASDAQ: SMMT) has ...